Mechanistic analysis for anti-RANKL antibody drug associated severe adverse reactions

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670265
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Applied pharmacology
• Research Institution: The University of Tokyo
• Principal Investigator: Kariya Yoshiaki 東京大学, 医学部附属病院, 助教 (20633168)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: システム薬理学 / 毒性予測

Outline of Final Research Achievements

Denosumab, an anti-RANKL antibody drug, has been clinically used in recent years. However, it has been suspected that Denosumab has a potential to cause severe hypocalcemia. Since drug adverse reactions (ADR) often occur under the mechanisms which are not expected at development, there are difficulties in revealing such mechanisms in many cases. Overcoming these difficulties leads to mechanism based ADR management, resulting in safer drug therapy. Therefore, in this research, we have established a method to obtain the clues for ADR mechanisms based on systems-pharmacological techniques. With this method, we approached the mechanism behind Denosumab inducing hypocalcemia.

Free Research Field

システム薬理学